Followers | 49 |
Posts | 2419 |
Boards Moderated | 0 |
Alias Born | 12/31/2014 |
Friday, February 07, 2020 9:54:22 AM
With respect, I disagree. The stock price is most likely going to remain where it is for a while, but I don't think that marketing is the problem. I see bigger issues such as the FDA and their lack of involvement with CBD in general.
While CVSI sits on the OTC, this is not some sub-penny stock that barely exists and is driven by daily press releases. This is a bonafide company with millions in annual revenue, that makes an industry leading product, and turns a profit doing it. Press releases are nice, but they won't fix the real problem of the FDA sitting on their hands.
The way I see it, the FDA does their job, releases the guidances we are all waiting for.. then next up is the NASDAQ guys approving the application for membership, and then it's off to the races. Until then, here we are.
Just my humble opinion.
A fool and his money is a friend indeed.
Recent CVSI News
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 02:36:49 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:21:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 01:32:15 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM